{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:41:35Z","timestamp":1775191295643,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.oret.2024.07.012","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T01:39:44Z","timestamp":1721439584000},"page":"13-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-5599","authenticated-orcid":false,"given":"Arshad M.","family":"Khanani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sarraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Tadayoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-845X","authenticated-orcid":false,"given":"David T.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6340-557X","authenticated-orcid":false,"given":"Insaf","family":"Saffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinfemichael","family":"Gedif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2024.07.012_bib1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2024.07.012_bib2","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2024.07.012_bib3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2024.07.012_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ajo.2007.06.014","article-title":"Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration","volume":"144","author":"Coscas","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2024.07.012_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ajo.2013.06.024","article-title":"Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography","volume":"156","author":"Nagiel","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2024.07.012_bib7","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1167\/iovs.18-26478","article-title":"Volumetric analysis of vascularized serous pigment epithelial detachment progression in neovascular age-related macular degeneration using optical coherence tomography angiography","volume":"60","author":"Au","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2024.07.012_bib8","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib9","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/bjophthalmol-2014-305186","article-title":"Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy","volume":"98","author":"Ritter","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2024.07.012_bib10","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.ophtha.2016.07.007","article-title":"Ranibizumab treatment for pigment epithelial detachment secondary to neovascular age-related macular degeneration: post hoc analysis of the HARBOR study","volume":"123","author":"Sarraf","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib11","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","article-title":"Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration","volume":"122","author":"Schmidt-Erfurth","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib13","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","article-title":"Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration","volume":"121","author":"Simader","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib14","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","article-title":"Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW Trials","volume":"123","author":"Waldstein","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ophtha.2015.09.013","article-title":"Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD","volume":"123","author":"Waldstein","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib17","first-page":"10","article-title":"Pigment epithelial detachment thickness and variability impacts visual outcomes in patients with neovascular age-related macular degeneration","volume":"44","author":"Sarraf","year":"2024","journal-title":"Retina"},{"key":"10.1016\/j.oret.2024.07.012_bib18","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib19","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration","volume":"244","author":"Tadayoni","year":"2021","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2024.07.012_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/bjo-2023-323577","article-title":"Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER","volume":"108","author":"Sadda","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2024.07.012_bib24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1167\/iovs.11-8188","article-title":"Automated characterization of pigment epithelial detachment by optical coherence tomography","volume":"53","author":"Lee","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2024.07.012_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.oret.2022.09.007","article-title":"OCT risk factors for development of atrophy in eyes with intermediate age-related macular degeneration","volume":"7","author":"Hirabayashi","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2024.07.012_bib26","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/IAE.0000000000000130","article-title":"Multilayered pigment epithelial detachment in neovascular age-related macular degeneration","volume":"34","author":"Rahimy","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.oret.2024.07.012_bib27","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/s41433-022-02092-5","article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies","volume":"37","author":"Lally","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2024.07.012_bib28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.07.012_bib30","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1097\/IAE.0000000000003556","article-title":"A\u00a0consensus on risk mitigation for brolucizumab in neovascular age-related macular degeneration: patient selection, evaluation, and treatment","volume":"42","author":"Holz","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.oret.2024.07.012_bib31","article-title":"Intraocular inflammation secondary to intravitreal brolucizumab treated successfully with sub-tenon triamcinolone: a case report","volume":"25","author":"Kurup","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.oret.2024.07.012_bib32","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1038\/s41598-022-10578-1","article-title":"One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 macular neovascularization","volume":"12","author":"Matsumoto","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2024.07.012_bib33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10384-021-00818-8","article-title":"Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy","volume":"65","author":"Kataoka","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.oret.2024.07.012_bib34","first-page":"2666","article-title":"Switching to brolucizumab in neovascular age-related macular degeneration incompletely responsive to ranibizumab or aflibercept: real-life 6 month outcomes","volume":"10","author":"Haensli","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.oret.2024.07.012_bib35","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1167\/iovs.11-8023","article-title":"Simple estimation of clinically relevant lesion volumes using spectral domain-optical coherence tomography in neovascular age-related macular degeneration","volume":"52","author":"Heussen","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302400335X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302400335X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T08:13:21Z","timestamp":1735805601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246865302400335X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S246865302400335X"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2024.07.012","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2024.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}